PIC Therapeutics

Executive Summary

PIC Therapeutics is a private, preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel small molecule therapies that target the eIF4A RNA helicase. The company's platform aims to inhibit the eIF4F complex, a key node in oncogenic translation, offering a differentiated approach to treat cancers and metabolic diseases. Founded in 2018, PIC Therapeutics leverages expertise in RNA biology and translation control to address high unmet needs in oncology and metabolic disorders. As a private company, it has not disclosed funding details or valuation, but its innovative approach targeting translation initiation positions it as an early-stage player in the precision oncology space. Given its preclinical stage, PIC Therapeutics has not yet advanced candidates into the clinic. The company's primary focus is on lead optimization and IND-enabling studies for its first program, likely targeting specific cancer subtypes driven by dysregulated translation. Success hinges on demonstrating compelling efficacy and safety in preclinical models, securing partnerships or financing to support clinical development, and navigating the competitive landscape of translation inhibitors. With no public pipeline data available, visibility into near-term milestones is limited, but the company's platform technology could attract interest from larger pharma seeking novel mechanisms in oncology.

Upcoming Catalysts (preview)

• Q2 2027Lead optimization and IND candidate nomination60% success
• Q4 2027Initiation of IND-enabling toxicology studies50% success
• Q3 2026Presentation of preclinical proof-of-concept data at a major conference70% success